EBS Q4 2024 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$446M

Q4 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$195M-29.6% YoY

Gross Profit

$137M70.1% margin

Operating Income

-$10M-4.9% margin

Net Income

-$31M-16.1% margin

EPS (Diluted)

$-0.59

QoQ Revenue Growth

-33.7%

Cash Flow

Operating Cash Flow

-$80M

Free Cash Flow

-$82M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$914M

Stockholders' Equity

$483M

Cash & Equivalents

$106M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$195M	$277M	-29.6%
Gross Profit	$137M	$169M	-19.3%
Operating Income	-$10M	-$44M	+78.3%
Net Income	-$31M	-$50M	+36.8%

Revenue Segments

Product

$182M93%

Contract Development And Manufacturing

$7M4%

Contracts and Grants

$5M3%

Geographic Segments

Services Segment

$7M100%